ATE523497T1 - Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen - Google Patents

Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen

Info

Publication number
ATE523497T1
ATE523497T1 AT07847181T AT07847181T ATE523497T1 AT E523497 T1 ATE523497 T1 AT E523497T1 AT 07847181 T AT07847181 T AT 07847181T AT 07847181 T AT07847181 T AT 07847181T AT E523497 T1 ATE523497 T1 AT E523497T1
Authority
AT
Austria
Prior art keywords
diabetes
treatment
obesitas
hydroxyphenyl
new
Prior art date
Application number
AT07847181T
Other languages
English (en)
Inventor
Preben Houlberg Olesen
Anders Klarskov Petersen
Flemming Elmelund Nielsen
Lise Brown Christiansen
Holger Claus Hansen
Original Assignee
High Point Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by High Point Pharmaceuticals Llc filed Critical High Point Pharmaceuticals Llc
Application granted granted Critical
Publication of ATE523497T1 publication Critical patent/ATE523497T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07847181T 2006-11-15 2007-11-15 Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen ATE523497T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200601486 2006-11-15
PCT/EP2007/062409 WO2008059026A1 (en) 2006-11-15 2007-11-15 Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes

Publications (1)

Publication Number Publication Date
ATE523497T1 true ATE523497T1 (de) 2011-09-15

Family

ID=39052661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07847181T ATE523497T1 (de) 2006-11-15 2007-11-15 Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen

Country Status (5)

Country Link
US (1) US7915299B2 (de)
EP (1) EP2097388B1 (de)
AT (1) ATE523497T1 (de)
CA (1) CA2669884A1 (de)
WO (1) WO2008059026A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2418202B1 (de) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivate als DGAT- Inhibitoren
US7939690B2 (en) 2006-11-15 2011-05-10 High Point Pharmaceuticals, Llc Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
EP2097391A1 (de) * 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC 2-(2-hydroxyphenyl)chinazolin-4-one, die sich für die behandlung von obesitas und diabetes eignen
EP2086951B1 (de) * 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Neue für die behandlung von obesitas und diabetes geeignete 2-(2-hydroxyphenyl)benzothiadiazine
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US8242284B1 (en) * 2009-09-21 2012-08-14 The United States Of America As Represented By The United States Department Of Energy Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making
CN102617478B (zh) * 2011-01-31 2015-07-15 华东理工大学 苯并咪唑、噁唑和噻唑衍生物的合成及其应用
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20150039551A (ko) * 2013-10-02 2015-04-10 제이에스알 가부시끼가이샤 경화성 조성물, 경화막 및 그의 형성 방법, 그리고 화합물
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
CA2937616A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
AU2016328436B2 (en) 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
BR112017026682A2 (pt) 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
WO2018129258A1 (en) 2017-01-06 2018-07-12 Gencia Corporation Novel phenyl derivatives
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
KR20210068399A (ko) 2018-08-06 2021-06-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 신경퇴행성 질병의 치료를 위한 피피에이알지씨1알파 활성제로서 2-아릴벤즈이미다졸

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3251837A (en) 1962-09-14 1966-05-17 Pfizer & Co C Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US3269955A (en) 1963-05-10 1966-08-30 American Cyanamid Co Method for emitting fluorescent light using fluorescent quinazolones
US3526627A (en) 1969-06-05 1970-09-01 American Cyanamid Co Method for preparation of quinazolones
JPS6025984A (ja) 1983-07-22 1985-02-08 Tokyo Inst Of Technol ベンゾチアジアジン誘導体の製造方法
US5240962A (en) 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
CZ120398A3 (cs) 1995-09-08 1998-12-16 Novo Nordisk A/S Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty
JP2000514041A (ja) 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病、低脂血、抗高血圧特性を有するチアゾリジンジオン化合物、それらの調製法、及びその薬学的組成物
AU4345297A (en) 1996-09-17 1998-04-14 Regents Of The University Of California, The Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
ES2199366T3 (es) 1996-12-31 2004-02-16 Dr. Reddy's Laboratories Ltd. Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas.
DE69727837T2 (de) 1997-05-02 2004-12-30 Dr. Reddy's Research Foundation, Hyderabad Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP0971917B1 (de) 1997-12-02 2002-02-06 Dr. Reddy's Research Foundation Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
JP2002527507A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
US6353018B1 (en) 1998-10-21 2002-03-05 Novo Nordisk A/S Compounds, their preparation and use
JP2002527502A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの調製及び使用
EP1123269A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Neuartige verbindungen, ihre herstellung und ihre verwendung
EP1123292A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Neuartige verbindungen, ihre herstellung und ihre verwendung
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
WO2000063191A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
PL351492A1 (en) 1999-04-16 2003-04-22 Reddys Lab Ltd Dr Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
WO2000063189A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
WO2000063190A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
EP1171438A1 (de) 1999-04-20 2002-01-16 Novo Nordisk A/S Verbindungen, ihre herstellung und ihre verwendung
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
EP1171414A1 (de) 1999-04-20 2002-01-16 Novo Nordisk A/S Verbindungen, ihre herstellung und ihre anwendung
JP2004067629A (ja) 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
US20040138301A1 (en) * 2002-11-08 2004-07-15 Hansen Birgit Sehested Chemical uncouplers for the treatment of obesity
KR100791252B1 (ko) 2003-01-23 2008-01-03 크리스탈지노믹스(주) 글리코겐 합성효소 키나아제 3β 활성 억제제, 이의제조방법 및 이를 유효성분으로 함유하는 약학 조성물
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
CA2545553A1 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. Methods for producing olfactory gpcrs
KR20060101500A (ko) 2003-11-25 2006-09-25 노보 노르디스크 에이/에스 신규한 살리실산 아닐리드
US20080113944A1 (en) * 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
AU2005316739A1 (en) * 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
WO2006066126A2 (en) * 2004-12-16 2006-06-22 Symyx Technologies, Inc. Phenol-heterocyclic ligands, metal complexes, and their uses as catalysts
EP2086951B1 (de) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Neue für die behandlung von obesitas und diabetes geeignete 2-(2-hydroxyphenyl)benzothiadiazine
US7939690B2 (en) 2006-11-15 2011-05-10 High Point Pharmaceuticals, Llc Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
EP2097391A1 (de) 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC 2-(2-hydroxyphenyl)chinazolin-4-one, die sich für die behandlung von obesitas und diabetes eignen

Also Published As

Publication number Publication date
EP2097388B1 (de) 2011-09-07
WO2008059026A1 (en) 2008-05-22
CA2669884A1 (en) 2008-05-22
EP2097388A1 (de) 2009-09-09
US7915299B2 (en) 2011-03-29
US20100063122A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
ATE523497T1 (de) Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
DE602007009865D1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin-7-olderivate als cxcr2-antagonisten
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
MA32811B1 (fr) Nouveaux composés
EA201001639A1 (ru) Композиции и способы их получения и применения
NO20072435L (no) CGRP-reseptorantagonister
ATE469895T1 (de) Cgrp-rezeptorantagonisten
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
ATE537170T1 (de) Cgrp-rezeptorantagonisten
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ATE548039T1 (de) Kondensierte heteroarylpyridyl- und phenylbenzensulfonamide als ccr2-modulatoren zur behandlung von entzündungen
SE0403006D0 (sv) New compounds
NO20082096L (no) Azaindol-2-karboksamidderivativer
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
NO20055741D0 (no) Nye kjemiske forbindelser
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
DE502007002185D1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties